$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018
[Report Updated: 01-03-2018]

Published by Current Partnering: 01 Mar 2018 | 195739 | In Stock
Related Topics: Abbott , AstraZeneca , Lilly , Novartis , Pfizer , Roche

Introduction

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.


This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2012 to 2018.


There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.


Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.


There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.


In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.


The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all collaborative R&D deals announced since 2012 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.


Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.


Chapter 4 provides a review of the leading collaborative R&D deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 5 provides a review of the top 50 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2012, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.


Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2012 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2012.


In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.


Key benefits


Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 provides the reader with the following key benefits:


In-depth understanding of collaborative R&D deal trends since 2012

Analysis of the structure of collaborative R&D agreements with numerous real life case studies

Comprehensive listing of over 4,500 collaborative R&D deals since 2012, together with deal terms, value and press release

Comprehensive access to actual collaborative R&D contracts entered into by the world’s life science companies

Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates

Insight into the terms included in a collaborative R&D agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.


Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 includes:


Trends in collaborative R&D dealmaking in the biopharma industry since 2012

Analysis of collaborative R&D deal structure

Case studies of real-life collaborative R&D deals

Comprehensive listing of over 4,500 collaborative R&D deals since 2012

Access to collaborative R&D contract documents

Key financial benchmarks for headline, upfront, milestone and royalty rates

The leading collaborative R&D deals by value since 2012

Most active collaborative R&D dealmakers since 2012

The leading collaborative R&D partnering resources


In Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 available deals and contracts are listed by:


Company A-Z

Headline value

Therapeutic area

Technology type


Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.


The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How do milestone align with clinical stage development phases?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018 [Report Updated: 01-03-2018]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in collaborative R&D dealmaking

    2.1. Introduction

    2.2. Definition of collaborative R&D partnering

    2.3. Success factors for collaborative R&D deals

    2.4. When collaborative R&D can be useful

    2.5. Attributes of collaborative R&D deals

    2.6. Trends in collaborative R&D deals since 2012

    2.6.1. Collaborative R&D dealmaking by year, 2012 to 2018

    2.6.2. Collaborative R&D dealmaking by phase of development, 2012 to 2018

    2.6.3. Collaborative R&D dealmaking by industry sector, 2012 to 2018

    2.6.4. Collaborative R&D dealmaking by therapy area, 2012 to 2018

    2.6.5. Collaborative R&D dealmaking by technology type, 2012 to 2018

    2.6.6. Collaborative R&D dealmaking by most active company, 2012 to 2018

    2.7. The future of collaborative R&D deals

    Chapter 3 – Overview of collaborative R&D deal structure

    3.1. Introduction

    3.2. Pure versus multi-component collaborative R&D deals

    3.3. Pure collaborative R&D agreement structure

    3.3.1. Example collaborative R&D agreements

    3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica

    3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals

    3.4. Collaborative R&D as part of a wider alliance agreement

    3.4.1. Example collaborative R&D agreements and their licensing clauses

    3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure

    3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals

    3.4.2. Example licensing option right clauses in collaborative R&D deals

    3.4.2.a. Case study 5: Forest Laboratories - Trevena

    3.4.2.b. Case study 6: Abbvie – Receptos

    Chapter 4 – Leading collaborative R&D deals

    4.1. Introduction

    4.2. Top collaborative R&D deals by value

    Chapter 5 – Top 50 most active collaborative R&D dealmakers

    5.1. Introduction

    5.2. Top 50 most active collaborative R&D dealmakers

    Chapter 6 – Collaborative R&D deal term financials

    6.1. Introduction

    6.2. Collaborative R&D partnering headline values

    6.3. Collaborative R&D deal upfront payments

    6.4. Collaborative R&D deal milestone payments

    6.5. Collaborative R&D royalty rates

    Chapter 7 – Collaborative R&D contract directory 2012 - 2018

    7.1. Introduction

    7.2. Collaborative R&D deals with contracts 2012 to 2018

    Appendices

    Appendix 1 – Collaborative R&D dealmaking by companies A-Z

    Appendix 2 – Collaborative R&D dealmaking by industry sector

    Appendix 3 – Collaborative R&D dealmaking by stage of development

    Appendix 4 – Collaborative R&D dealmaking by therapy area

    Appendix 5 – Collaborative R&D dealmaking by technology type

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    TABLE OF FIGURES

    Figure 1: Definition of collaborative R&D

    Figure 2: Situations where collaborative R&D can prove useful

    Figure 3: Key attributes of a collaborative R&D deal

    Figure 4: Trends in Collaborative R&D deal announcements, 2012 to 2018

    Figure 5: Collaborative R&D deals signed at each phase of development, 2012 to 2018

    Figure 6: Collaborative R&D deals by industry sector, 2012 to 2018

    Figure 7: Collaborative R&D deals by therapy area, 2012 to 2018

    Figure 8: Collaborative R&D deals by technology type, 2012 to 2018

    Figure 9: Top 50 most active collaborative R&D dealmakers, 2012 to 2018

    Figure 10: Collaborative R&D agreements – what should a contract include?

    Figure 11: Components of the collaborative R&D deal structure

    Figure 12: Top collaborative deals by value 2012 to 2018

    Figure 13: Most active collaborative R&D dealmakers 2012 to 2018

    Figure 14: Collaborative R&D deals with a headline value

    Figure 15: Collaborative R&D deals with an upfront value

    Figure 16: Collaborative R&D deals with a milestone value

    Figure 17: Collaborative R&D deals with a royalty rate value

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

195739 | CP2064

Number of Pages

2000

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Industrial Robotics Market by Type (Articulated, Cartesian, SCARA, Parallel, Collaborative Robots), Industry (Automotive, Electrical & Electronics, Metals & Machinery, Pharmaceuticals & Cosmetics), and Geography - Global Forecast to 2023
“Industrial robotics market projected to grow at a significant rate between 2017 and 2023”The indust...
14 Jul 2017 by MarketsandMarkets USD $5,650 More Info
Global Collaborative Robots Market Research 2011- 2022
SummaryCollaborative robots, or cobots as they are known to the cognoscenti, are robots that are des...
04 Jun 2017 by HeyReport USD $1,790 More Info
Food Robotics Market by Type (Articulated, Cartesian, Scara, Parallel, Cylindrical, Collaborative, Others), by Payload (Low, Medium, High), by Application (Palletizing, Packaging, Repackaging, Pick & Place, Processing, Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023
The global food robotics market is expected to reach ,612 million by 2023, from ,535 million in ...
01 Jun 2017 by Allied Market Research USD $5,370 More Info
Aerospace Robotics Market by Type (Articulated, Cartesian, Cylindrical, Spherical, SCARA, and Parallel), Technology (Traditional, Collaborative), Application (Drilling, Welding, Painting, Inspection) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Aerospace robotics market refers to the robotic technology used in aerospace industry for the manufa...
25 Apr 2017 by Allied Market Research USD $5,370 More Info
Aerospace Robotics Market by Type (Articulated, Cartesian, Cylindrical, Spherical, SCARA, and Parallel), Technology (Traditional, Collaborative), Application (Drilling, Welding, Painting, Inspection) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Aerospace robotics market refers to the robotic technology used in aerospace industry for the manufa...
01 Apr 2017 by Allied Market Research USD $5,370 More Info
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2017
The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012...
01 Feb 2017 by Current Partnering USD $2,995 More Info
Aerospace Robotics Market by Type (Scara, Cylindrical, Articulated, Catesian), Component (Controller, Processor, End Effector, Drive, Sensor) Technology (Traditional, Collaborative), Application and Region - Global Forecast to 2022
“Growing use of robotics to handle aircraft orders backlog is one of the key factors expected to dri...
06 Jan 2017 by MarketsandMarkets USD $5,650 More Info
Smart Education and Learning Market by Product (Hardware, Software, Service, Educational Content), User (Academic, Corporate), Learning Mode (Collaborative, Virtual Instructor, Simulation, Adaptive, Social, Blended), and Region - Global Forecast to 2021
“Increasing eLearning in the corporate and academic setups and widespread government initiatives is ...
06 Dec 2016 by MarketsandMarkets USD $7,150 More Info
Cloud-Based PLM Market by Application (Portfolio Management, Product Data Management, Collaborative Design and Engineering, Customer Management, Compliance Management), Organization Size, Vertical, and Region - Global Forecast to 2021
“Growing demand for integrated Product Lifecycle Management (PLM) application, strategic business pr...
09 Sep 2016 by MarketsandMarkets USD $5,650 More Info
Smart Robots Market by Component (Software, Hardware), Application (Collaborative Industrial Robots, Personal Service Robots, Professional Service Robots), by Geography (North America, Europe, APAC, RoW) - Analysis & Forecast to 2020
Smart robots are the autonomous robotic systems. They are being designed to perform independent task...
24 Jul 2015 by MarketsandMarkets USD $5,650 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018 [Report Updated: 01-03-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)